COMMUNIQUÉS West-GlobeNewswire

SS Innovations To Showcase the SSi Mantra Surgical Robotic System at SRS 2026
17/07/2026
Company’s advanced surgical robotic system will be on display, spotlighted in multiple breakout sessions, and featured in a kidney telesurgery to be broadcast live at the premier industry event FORT LAUDERDALE, Fla., [...]
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
17/07/2026
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect [...]
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/07/2026
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients [...]
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
17/07/2026
Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder [...]
Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
17/07/2026
RUTHERFORD, N.J. and SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™ ("Lōkahi") , a clinical-stage [...]
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
17/07/2026
Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolio Portfolio now positioned to address the [...]
BrewDog and Tilray Brands Unlock £1 Million Bar Tab for Football Fans Across England, Scotland and Ireland
17/07/2026
BrewDog and Tilray are keeping football’s biggest celebration alive by unlocking the £1 million bar tab at participating pubs 1 beginning July 20 because great football deserves celebrating, no matter who lifts the [...]
Orion Group Half-Year Financial Report January–June 2026
17/07/2026
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2026 17 JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2026 April–June 2026 Highlights Net sales totalled EUR 521.6 (April–June 2025: 416.5) [...]
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
17/07/2026
Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist Dimerix Limited (ASX: DXB) Mission will receive up to US$292 million in [...]
Orion Corporation’s financial reporting and Annual General Meeting in 2027
17/07/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 17 JULY 2026 at 10.30 EEST Orion Corporation’s financial reporting and Annual General Meeting in 2027 Orion Corporation will publish its Financial Statement [...]
European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
17/07/2026
Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, delivering a novel mechanism of action with antifibrotic and immunomodulatory [...]
Enjoin Reports 923% Average ROI Delivered in Q1 2026
17/07/2026
Photo Courtesy of Enjoin NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Enjoin, a leading tech-enabled provider of Pre-Bill Chart Reviews and trusted revenue integrity partner to health systems and children's [...]
Marketing Veteran Bryan Dulaney is advising SafeSpace Global on Growth Strategy
17/07/2026
NASHVILLE, TN., July 16, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC), (“SafeSpace Global” or the “Company”), an AI-powered physical safety and monitoring platform for regulated care environments [...]
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
16/07/2026
HONG KONG, July 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in [...]
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
16/07/2026
AUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2026 after the [...]
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
16/07/2026
Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichment ANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the [...]
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
16/07/2026
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI ( [...]
DBV Technologies publie son Rapport Financier Semestriel 2026 ― Modalités de mise à disposition ou de consultation
16/07/2026
Châtillon, France, le 16 juillet 2026 DBV Technologies publie son Rapport Financier Semestriel 2026 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : [...]
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
16/07/2026
Châtillon, France, July 16, 2026 DBV Te c hnologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq [...]

Pages